AU2015372767B2 - Glucagon derivatives - Google Patents

Glucagon derivatives Download PDF

Info

Publication number
AU2015372767B2
AU2015372767B2 AU2015372767A AU2015372767A AU2015372767B2 AU 2015372767 B2 AU2015372767 B2 AU 2015372767B2 AU 2015372767 A AU2015372767 A AU 2015372767A AU 2015372767 A AU2015372767 A AU 2015372767A AU 2015372767 B2 AU2015372767 B2 AU 2015372767B2
Authority
AU
Australia
Prior art keywords
lys
peptide
xaa
glu
artificial sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015372767A
Other languages
English (en)
Other versions
AU2015372767A1 (en
Inventor
Jae Hyuk Choi
Sung Youb Jung
Se Chang Kwon
Jong Suk Lee
Chang Ki Lim
Young Jin Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AU2015372767A1 publication Critical patent/AU2015372767A1/en
Application granted granted Critical
Publication of AU2015372767B2 publication Critical patent/AU2015372767B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015372767A 2014-12-30 2015-12-30 Glucagon derivatives Active AU2015372767B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0193691 2014-12-30
KR1020140193691A KR102418477B1 (ko) 2014-12-30 2014-12-30 글루카곤 유도체
PCT/KR2015/014481 WO2016108617A1 (en) 2014-12-30 2015-12-30 Glucagon derivatives

Publications (2)

Publication Number Publication Date
AU2015372767A1 AU2015372767A1 (en) 2017-07-13
AU2015372767B2 true AU2015372767B2 (en) 2020-07-16

Family

ID=56284668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015372767A Active AU2015372767B2 (en) 2014-12-30 2015-12-30 Glucagon derivatives

Country Status (18)

Country Link
US (3) US10513550B2 (enExample)
EP (1) EP3240802B1 (enExample)
JP (1) JP6758297B2 (enExample)
KR (1) KR102418477B1 (enExample)
CN (1) CN107250155B (enExample)
AR (1) AR103323A1 (enExample)
AU (1) AU2015372767B2 (enExample)
BR (1) BR112017013845A2 (enExample)
CA (1) CA2972001C (enExample)
EA (1) EA036479B1 (enExample)
IL (1) IL253001B (enExample)
MX (1) MX389593B (enExample)
PH (1) PH12017501205A1 (enExample)
SG (2) SG10201906912VA (enExample)
TW (1) TWI696631B (enExample)
UA (1) UA122967C2 (enExample)
WO (1) WO2016108617A1 (enExample)
ZA (1) ZA201704328B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230304A1 (es) * 2014-12-30 2023-02-13 Hanmi Pharm Ind Co Ltd Derivados de glucagon como agentes hipoglucemicos y antiobesidad
CN108025041A (zh) 2015-06-30 2018-05-11 韩美药品株式会社 胰高血糖素衍生物和包含其长效缀合物的组合物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
HK1258177A1 (en) 2015-12-31 2019-11-08 Hanmi Pharm. Co., Ltd. Persistent conjugate of triple activator activating glucagon, glp-1 and gip receptor
CN112912095A (zh) * 2018-07-19 2021-06-04 D&D制药技术股份有限公司 包括多肽的药物组合物
JP2025526148A (ja) 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012169798A2 (en) * 2011-06-10 2012-12-13 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
JP3895109B2 (ja) 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
AU2006258841B2 (en) 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2007030375A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
EP2471811B1 (en) 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
WO2009015763A1 (en) 2007-07-27 2009-02-05 Bayer Cropscience Ag Ternary active compound combinations
CN101765976B (zh) 2007-08-07 2014-03-12 富士通株式会社 错误检测装置和错误校正/错误检测解码装置和方法
WO2009040086A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of salusin-alpha as a therapeutic agent
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
FR2936441B1 (fr) 2008-09-26 2012-12-07 Rhodia Operations Article polyamide composite
KR20110126591A (ko) * 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
PT2408800T (pt) 2009-03-20 2016-08-23 Hanmi Science Co Ltd Método para preparar um conjugado específico de local de um polipéptido fisiologicamente ativo
BRPI1014508A2 (pt) 2009-06-16 2016-04-05 Univ Indiana Res & Tech Corp análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
BR112012018104A2 (pt) * 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
CN102834108A (zh) 2010-01-27 2012-12-19 印第安纳大学研究及科技有限公司 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
CN103179979A (zh) 2010-06-24 2013-06-26 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012032567A1 (ja) 2010-09-06 2012-03-15 パナソニック株式会社 表示装置及びその制御方法
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
CN103402536A (zh) 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
TR201901402T4 (tr) 2011-06-17 2019-02-21 Hanmi Science Co Ltd Oksintomodulin ve bir immünoglobulin fragmanı içeren bir konjugat ve onun kullanımı.
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
WO2013192129A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EP3610856B1 (en) 2012-11-06 2021-08-18 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
AU2014255608B2 (en) * 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012169798A2 (en) * 2011-06-10 2012-12-13 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Also Published As

Publication number Publication date
US20180002395A1 (en) 2018-01-04
SG11201705130XA (en) 2017-07-28
CA2972001C (en) 2024-07-02
KR20160082026A (ko) 2016-07-08
IL253001B (en) 2022-04-01
US20200140515A1 (en) 2020-05-07
EP3240802A4 (en) 2018-10-10
EP3240802A1 (en) 2017-11-08
US12018060B2 (en) 2024-06-25
EA201791498A1 (ru) 2017-10-31
EP3240802B1 (en) 2021-07-21
IL253001A0 (en) 2017-08-31
TW201632546A (zh) 2016-09-16
US10513550B2 (en) 2019-12-24
PH12017501205A1 (en) 2017-10-18
JP2018505153A (ja) 2018-02-22
MX2017008715A (es) 2017-11-17
AR103323A1 (es) 2017-05-03
TWI696631B (zh) 2020-06-21
EA036479B1 (ru) 2020-11-16
MX389593B (es) 2025-03-20
SG10201906912VA (en) 2019-09-27
NZ733649A (en) 2024-07-26
KR102418477B1 (ko) 2022-07-08
US20220025012A1 (en) 2022-01-27
CA2972001A1 (en) 2016-07-07
UA122967C2 (uk) 2021-01-27
US11254724B2 (en) 2022-02-22
CN107250155A (zh) 2017-10-13
CN107250155B (zh) 2021-08-10
HK1246323A1 (en) 2018-09-07
JP6758297B2 (ja) 2020-09-23
WO2016108617A1 (en) 2016-07-07
ZA201704328B (en) 2021-01-27
NZ771617A (en) 2024-09-27
BR112017013845A2 (pt) 2018-01-02
AU2015372767A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
AU2020201322B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US12018060B2 (en) Glucagon derivatives
US11135271B2 (en) Glucagon derivatives with improved stability
HK1246323B (en) Glucagon derivatives
HK40010066A (en) Glucagon derivative
HK40002934A (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ731342B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ618810B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ755534B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ734808B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ740049B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)